Form D · Pharmaceuticals
GENEREX BIOTECHNOLOGY CORP
Miramar, FL · CIK 0001059784
Offering snapshot reported Sep 11, 2020 · SEC filing
- Reported sold
- $2M Indefinite offering
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 4, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 11, 2020 | Initial | $2,000,000 | No comparison | 3 | SEC filing |
| Sep 5, 2012 | Initial | $750,000 | No comparison | 7 | SEC filing |
| Feb 7, 2012 | Initial | $2,000,000 | No comparison | 7 | SEC filing |
| Apr 8, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 23, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 20, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 20, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 3, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 21, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 30, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 14, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 11, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $80K
- Finders' fees
- $0
- Form D file number
- 021-375354
Common shares of the company's common stock and warrants were issued in a private placement, as disclosed on the issuer's Current Report on Form 8-K, filed with the SEC on August 7, 2020.
Represents a Placement Agent Fee payable to Dawson James Securities, Inc.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Dawson James Securities, Inc | 130645 |
Source: Form D, filed Sep 11, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Anderson | Director |
| James H. Anderson, Jr., M.D. | Director |
| John P. Barratt | Director |
| David Brusegard, Ph.D. | Executive |
| Mark Corrao | Executive |
| Anthony Crisci | Executive |
| Craig Eagle | Director |
| Stephen Fellows | Executive |
| Mark A. Fletcher | Director, Executive |
| Nola E. Masterson | Director |
| Brian Mc Gee | Director |
| Joseph Moscato | Director, Executive |
| Mark Prioletti | Director |
| Richard Purcell | Executive |
| Andrew Ro | Director, Executive |
| Lawrence Salvo | Director |
| Jason Terrell | Executive |
| Terry Thompson | Executive |
| Eric Von Hofe, Ph.D. | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
10102 Usa Today Way
Miramar, FL, 33025
Miramar, FL, 33025